• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Clinical observation on 16 cases of DEK-NUP214 fusion gene positive acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation].

作者信息

Xia J, Zhao Y, Wu X J, Qiu H Y, Tang X W, Wang Y, Jin Z M, Miao M, Ma X, Wu D P, Chen S N, Chen F

机构信息

Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215000, China Department of Hematology, Soochow Hopes Hematology Hospital, Suzhou 215000, China.

Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215000, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1041-1044. doi: 10.3760/cma.j.issn.0253-2727.2023.12.014.

DOI:10.3760/cma.j.issn.0253-2727.2023.12.014
PMID:38503531
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10834877/
Abstract
摘要

相似文献

1
[Clinical observation on 16 cases of DEK-NUP214 fusion gene positive acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation].[异基因造血干细胞移植治疗16例DEK-NUP214融合基因阳性急性髓系白血病的临床观察]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1041-1044. doi: 10.3760/cma.j.issn.0253-2727.2023.12.014.
2
[Analysis of therapeutic effects of allogeneic hematopoietic stem cell transplantation in 12 patients with DEK-NUP214 fusion gene positive acute myeloid leukemia].[12例DEK-NUP214融合基因阳性急性髓系白血病患者异基因造血干细胞移植的疗效分析]
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):383-387. doi: 10.3760/cma.j.cn121090-20230913-00115.
3
t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.t(6;9)(p22;q34)/DEK-NUP214重排的儿童髓系白血病：一项对62例患者的国际研究
Haematologica. 2014 May;99(5):865-72. doi: 10.3324/haematol.2013.098517. Epub 2014 Jan 17.
4
[Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].[DEK-NUP214融合基因在急性髓系白血病患者异基因造血干细胞移植后的预后意义]
Zhonghua Nei Ke Za Zhi. 2021 Oct 1;60(10):868-874. doi: 10.3760/cma.j.cn112138-20201015-00868.
5
Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.伴 t(6;9)(p22;q34.1)/DEK-NUP214 骨髓增生异常综合征是否应更好地归类为急性髓系白血病？107 例多中心研究。
Mod Pathol. 2021 Jun;34(6):1143-1152. doi: 10.1038/s41379-021-00741-w. Epub 2021 Feb 8.
6
-Fusion Identified by RNA-Sequencing of an Acute Myeloid Leukemia with t(9;12)(q34;q15).- 通过RNA测序在伴有t(9;12)(q34;q15)的急性髓系白血病中鉴定出融合现象
Cancer Genomics Proteomics. 2017 Nov-Dec;14(6):437-443. doi: 10.21873/cgp.20053.
7
Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.DEK-NUP214融合蛋白的强制表达通过mTOR的上调促进增殖。
BMC Cancer. 2013 Sep 27;13:440. doi: 10.1186/1471-2407-13-440.
8
Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease.嗜酸性粒细胞嵌合现象在DEK-NUP214阳性急性髓系白血病复发与慢性移植物抗宿主病鉴别诊断中的应用
J Clin Pathol. 2015 Nov;68(11):950-2. doi: 10.1136/jclinpath-2015-203013. Epub 2015 Jul 20.
9
The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.DEK-NUP214阳性急性髓系白血病患者的复发动力学
Eur J Haematol. 2015 Nov;95(5):436-41. doi: 10.1111/ejh.12511. Epub 2015 Mar 13.
10
SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines.急性髓系白血病和 T 细胞急性淋巴细胞白血病源性细胞系中的 SET-NUP214 融合。
J Hematol Oncol. 2009 Jan 23;2:3. doi: 10.1186/1756-8722-2-3.

本文引用的文献

1
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.米哚妥林降低 FLT3 突变型急性髓系白血病的复发率：CALGB 10603/RATIFY 试验联盟。
Leukemia. 2021 Sep;35(9):2539-2551. doi: 10.1038/s41375-021-01179-4. Epub 2021 Mar 2.
2
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.索拉非尼维持治疗伴 FLT3-ITD 急性髓系白血病行异基因造血干细胞移植患者：一项开放标签、多中心、随机 3 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1201-1212. doi: 10.1016/S1470-2045(20)30455-1. Epub 2020 Aug 10.
3
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.索拉非尼联合标准疗法与安慰剂联合标准疗法治疗 60 岁及以下初诊急性髓系白血病患者（SORAML）：一项多中心、2 期、随机对照试验。
Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.
4
t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.t(6;9)(p22;q34)/DEK-NUP214重排的儿童髓系白血病：一项对62例患者的国际研究
Haematologica. 2014 May;99(5):865-72. doi: 10.3324/haematol.2013.098517. Epub 2014 Jan 17.
5
Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis.供者造血干细胞移植治疗伴有 t(6;9)(p23;q34)的急性髓系白血病显著改善患者预后：一项配对分析。
Leukemia. 2012 Mar;26(3):461-4. doi: 10.1038/leu.2011.229. Epub 2011 Aug 26.
6
The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation.t(6;9) 相关的 DEK/CAN 融合蛋白将一群长期重建造血干细胞作为白血病转化的靶标。
Leukemia. 2010 Nov;24(11):1910-9. doi: 10.1038/leu.2010.180. Epub 2010 Sep 9.
7
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.一项针对69例t(6;9)(p23;q34)急性髓系白血病患者的回顾性研究强调，对于罕见的“预后不良”髓系恶性肿瘤，需要开展一项前瞻性、多中心研究。
Leukemia. 2006 Jul;20(7):1295-7. doi: 10.1038/sj.leu.2404233. Epub 2006 Apr 20.
8
DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification.髓系恶性肿瘤的DEK-CAN分子监测有助于治疗分层。
Leukemia. 2005 Aug;19(8):1338-44. doi: 10.1038/sj.leu.2403835.
9
Development of a D-FISH method to detect DEK/CAN fusion resulting from t(6;9)(p23;q34) in patients with acute myelogenous leukemia.一种用于检测急性髓性白血病患者因t(6;9)(p23;q34)导致的DEK/CAN融合的D-FISH方法的开发。
Leukemia. 2005 Jan;19(1):126-31. doi: 10.1038/sj.leu.2403557.
10
Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations.伴有t(6;9)(p23;q34)的急性髓系白血病与发育异常及高频flt3基因突变相关。
Am J Clin Pathol. 2004 Sep;122(3):348-58. doi: 10.1309/5DGB-59KQ-A527-PD47.